SG
Steve Gillis, PhD
Managing Director, ARCH Venture Partners; Executive Chairman of the Board
Bitterroot BioTherapeutic Areas
Bitterroot Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anti-CD47 Therapy | Atherosclerosis / Prevention of Major Adverse Cardiovascular Events (MACE) | Pre-clinical |